2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3226

Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Abstract Number: 3227

Modelling Primary Sjögren’s Syndrome Using Salivary Gland Stem Cells
Abstract Number: 3228

Specific T Cell and B Cell Distributions Characterize Subgroups of Patients with Primary Sjögren’s Syndrome and Are Associated with Disease Activity and Pro-Inflammatory Cytokine Expression
Abstract Number: 3229

Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Abstract Number: 3230

Genome-Wide Association Study Identifies Novel Sjögren’s Syndrome Risk Loci in the Regions of NAB1, TYK2, and PTTG1-mir146a
Abstract Number: 3231

miR200b-5p Expression in Minor Salivary Glands (MSG): A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?
Abstract Number: 3232

Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation
Abstract Number: 3233

Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests
Abstract Number: 3234

Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys
Abstract Number: 3235

Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus: Up to 7 Years of Treatment Exposure
Abstract Number: 3236

Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study
Abstract Number: 3237

Responsiveness and Its Magnitude in the 36-Item Short Form Health Survey and the Lupus Quality of Life Questionnaire in Patients with Active Disease
Abstract Number: 3238

Depression Symptoms throughout the Lifespan in a Low-Income, Minority Cohort of Lupus Patients: Who Is at Risk?
Abstract Number: 3239

Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Abstract Number: 3240

Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].